Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neurofibromatosis 2 × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 15 Neoplasm Metastasis 7 Lung Neoplasms 5 Neoplasms 3 Adenocarcinoma 3 Recurrence 2 Lymphoma, Large-Cell, Anaplastic 2 Granuloma, Plasma Cell 2 Colorectal Neoplasms 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Relapsed Pediatric Solid Tumor 1 Rare Tumor 1 Neurofibromatosis 2 1 Lymphoma, Follicular 1 Lung Adenocarcinoma Metastatic 1 Glioma 1 Glioblastoma 1 Gallbladder Neoplasms 1 Endometrial Cancer Recurrent 1 Diffuse Intrinsic Pontine Glioma 1 Castration-resistant Prostate Cancer 1 Carcinoma, Squamous Cell 1 Carcinoma, Lobular 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

Everolimus 4 Bevacizumab 4 Sirolimus 2 Lapatinib 2 vistusertib 1 temsirolimus 1 neratinib 1 icotinib 1 brigatinib 1 Vascular Endothelial Growth Factor A 1 Valproic Acid 1 Sunitinib 1 Immunoglobulin G 1 HDAC-42 1 Exome 1 Endostatins 1 Doxycycline 1 Disulfides 1 Crizotinib 1 Cetuximab 1 Axitinib 1 Aspirin 1 AZD 6244 1 89Zr-bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04283669 2026-03-13

NF110

University of Alabama at Birmingham

Phase 2 Completed

12 enrolled 5 charts

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡